Nelarabine,rituximab
novartis
['leusm']
dr. boissel from reports on graall-2014 -&gt; utilized end-induction mrd status as sole indication for hct rather than traditional hr features -&gt; 743 pts; fewer w/ indication for hct than graall-2005 (30 v 65%) &amp; fewer hct in cr1 (38 vs 23%). #leusm #ash22 #allsm 1/2 
Leukemia/cell therapy doc & AYA Leukemia Program Leader at @MSKCancerCenter w/ special interest in ALL. Indie rock & Boston sports fan. Opinions=my own.??????